Italy seeks 1.2 bn euros in anti-trust damages from Roche, Novartis

Italy's health ministry is seeking 1.2 billion euros ($1.6 million) in compensation from Swiss pharma giants Novartis and Roche for the manipulation of sales of a cheap drug used to treat eye problems, Italian media reported Wednesday.

The ministry's move came after Italy's antitrust body fined the two firms 182.5 million euros over their "illicit deal to prevent the use of a very cheap drug, Avastin, in treating" sight problems.

The antitrust body said the two pharma giants had colluded with the aim of boosting the sales of a more expensive product, Lucentis. It also claimed that they steered health services and doctors away from Avastin by describing it as more dangerous.

Both Roche and Novartis market Lucentis as the best medicine for the eye disease known as .

Novartis has rejected the anti-competition accusations and has said it would appeal against the fine.

add to favorites email to friend print save as pdf

Related Stories

Novartis tries to make UK hospitals use $1000 drug

Apr 24, 2012

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

FDA warns of another compounding pharmacy recall

Mar 20, 2013

(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.

FDA panel unanimously backs Regeneron eye drug

Jun 17, 2011

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

Japan prosecutors raid Novartis over drug ad scandal

Feb 19, 2014

Japanese prosecutors on Wednesday raided the offices of the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, local media said.

Recommended for you

Determine patient preferences by means of conjoint analysis

15 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments